IL124803A0 - Coralyne analogs as topoisomerase inhibitors - Google Patents

Coralyne analogs as topoisomerase inhibitors

Info

Publication number
IL124803A0
IL124803A0 IL12480397A IL12480397A IL124803A0 IL 124803 A0 IL124803 A0 IL 124803A0 IL 12480397 A IL12480397 A IL 12480397A IL 12480397 A IL12480397 A IL 12480397A IL 124803 A0 IL124803 A0 IL 124803A0
Authority
IL
Israel
Prior art keywords
coralyne
analogs
topoisomerase inhibitors
topoisomerase
inhibitors
Prior art date
Application number
IL12480397A
Other languages
English (en)
Original Assignee
Univ Rutgers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rutgers filed Critical Univ Rutgers
Publication of IL124803A0 publication Critical patent/IL124803A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D455/00Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL12480397A 1996-02-12 1997-02-11 Coralyne analogs as topoisomerase inhibitors IL124803A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1145296P 1996-02-12 1996-02-12
US3216196P 1996-10-01 1996-10-01
PCT/US1997/001676 WO1997029106A1 (en) 1996-02-12 1997-02-11 Coralyne analogs as topoisomerase inhibitors

Publications (1)

Publication Number Publication Date
IL124803A0 true IL124803A0 (en) 1999-01-26

Family

ID=26682407

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12480397A IL124803A0 (en) 1996-02-12 1997-02-11 Coralyne analogs as topoisomerase inhibitors

Country Status (18)

Country Link
EP (1) EP0888346B1 (pt)
JP (1) JP2000504687A (pt)
KR (1) KR19990082488A (pt)
CN (1) CN1067070C (pt)
AU (1) AU710070C (pt)
BR (1) BR9707425A (pt)
CA (1) CA2241551A1 (pt)
CZ (1) CZ254498A3 (pt)
DE (1) DE69705112T2 (pt)
ES (1) ES2161442T3 (pt)
HU (1) HUP9900413A3 (pt)
IL (1) IL124803A0 (pt)
NO (1) NO983669L (pt)
NZ (1) NZ330705A (pt)
PL (1) PL328402A1 (pt)
PT (1) PT888346E (pt)
TR (1) TR199801555T2 (pt)
WO (1) WO1997029106A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW460464B (en) * 1996-11-25 2001-10-21 Nippon Kayaku Kk Novel phenanthridinium derivative having an anti-tumor activity and pharmaceutical composition containing the same
US6140328A (en) * 1997-12-12 2000-10-31 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
US6063801A (en) 1998-02-12 2000-05-16 Rutgers, The State University Of New Jersey Heterocyclic topoisomerase poisons
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
CN1093129C (zh) * 1999-08-19 2002-10-23 广州市海科生物技术有限公司 一种具有抗肿瘤生理活性的尖叶唐松草阿原碱及其提取方法
US6740650B2 (en) 1999-10-29 2004-05-25 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
DE60231426D1 (de) 2001-11-14 2009-04-16 Univ Rutgers Solubilisierte topoisomerase-gift-mittel
DE60235287D1 (de) 2001-11-14 2010-03-25 Univ Rutgers Löslich gemachte topoisomerase-gifte
EP1453506B1 (en) 2001-11-14 2008-04-02 Rutgers, The State University Topoisomerase poison agents
AU2003268075A1 (en) 2002-08-09 2004-02-25 Edmond J. Lavoie Nitro and amino substituted dibenzonaphthyridines as topoisomerase agents
WO2004014862A1 (en) 2002-08-09 2004-02-19 Rutgers, The State University Nitro and amino substituted heterocycles as topoisomerase i targeting agents
AU2003265406A1 (en) 2002-08-09 2004-02-25 Edmond J. Lavoie Nitro and amino substituted topoisomerase agents
WO2004044174A2 (en) 2002-11-12 2004-05-27 Rutgers, The State University Topoisomerase-targeting agents
KR101431279B1 (ko) 2005-07-29 2014-08-20 리스버로직스 코퍼레이션 복합 질환의 예방 및 치료용 약학적 조성물 및 삽입가능한의료 장치에 의한 이의 전달
MX2009008099A (es) 2007-02-01 2009-12-14 Resverlogix Corp Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares.
EP2014651A1 (en) * 2007-07-12 2009-01-14 Exonhit Therapeutics SA Compounds and methods for modulating Rho GTPases
JP5602728B2 (ja) 2008-06-26 2014-10-08 レスバーロジックス コーポレイション キナゾリノン誘導体の製造方法
EP2382194B1 (en) 2009-01-08 2014-03-12 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
JP5773888B2 (ja) 2009-03-06 2015-09-02 ラットガーズ,ザ・ステート・ユニバーシティ・オブ・ニュージャージー 癌治療に用いられるメチレンジオキシベンゾ[i]フェナントリジン誘導体
WO2010106436A2 (en) 2009-03-18 2010-09-23 Resverlogix Corp. Novel anti-inflammatory agents
SI2421533T1 (sl) 2009-04-22 2019-01-31 Resverlogix Corp. Nova protivnetna sredstva
WO2010127363A1 (en) 2009-05-01 2010-11-04 Rutgers, The State University Of New Jersey Toposiomerase inhibitors
US8188109B2 (en) * 2009-07-20 2012-05-29 Naxospharma S.R.L. Benzoquinolizinium salt derivatives as anticancer agents
CN102746292B (zh) * 2011-04-18 2015-03-18 中国医学科学院医药生物技术研究所 环化的小檗碱衍生物及其制备方法和用途
DK2773354T3 (da) 2011-11-01 2019-08-05 Resverlogix Corp Oralformuleringer med øjeblikkelig frigivelse for substituerede quinazolinoner
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
CA2895905A1 (en) 2012-12-21 2014-06-26 Zenith Epigenetics Corp. Novel heterocyclic compounds as bromodomain inhibitors
US9642846B2 (en) 2013-03-15 2017-05-09 Georgetown University Antifungal drugs
CN109851617B (zh) 2013-08-23 2022-08-16 润新生物公司 化学实体、组合物和方法
WO2016133935A1 (en) * 2015-02-17 2016-08-25 Neupharma, Inc. Certain chemical entities, compositions, and methods
EP3268007B1 (en) 2015-03-13 2022-11-09 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
CN105541714A (zh) * 2015-12-16 2016-05-04 浙江普洛康裕制药有限公司 一种罂粟碱及盐酸罂粟碱的制备方法
CN109219610A (zh) 2016-04-04 2019-01-15 新泽西州立拉特格斯大学 拓扑异构酶毒物
US10544106B2 (en) 2016-08-15 2020-01-28 Neupharma, Inc. Certain chemical entities, compositions, and methods
CN110759963A (zh) * 2018-07-25 2020-02-07 中山大学 一种稠环类化合物及其制备方法和用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126351A (en) * 1991-01-24 1992-06-30 Glaxo Inc. Antitumor compounds
US5223506A (en) * 1991-06-04 1993-06-29 Glaxo Inc. Cyclic antitumor compounds

Also Published As

Publication number Publication date
TR199801555T2 (xx) 1998-11-23
CN1067070C (zh) 2001-06-13
BR9707425A (pt) 1999-07-20
PT888346E (pt) 2001-10-31
JP2000504687A (ja) 2000-04-18
NZ330705A (en) 2000-03-27
DE69705112D1 (en) 2001-07-12
KR19990082488A (ko) 1999-11-25
AU710070C (en) 2001-08-30
AU2115597A (en) 1997-08-28
NO983669D0 (no) 1998-08-11
CA2241551A1 (en) 1997-08-14
NO983669L (no) 1998-09-23
CZ254498A3 (cs) 1998-12-16
DE69705112T2 (de) 2002-03-21
EP0888346B1 (en) 2001-06-06
AU710070B2 (en) 1999-09-16
EP0888346A1 (en) 1999-01-07
HUP9900413A2 (hu) 1999-05-28
PL328402A1 (en) 1999-01-18
CN1211252A (zh) 1999-03-17
WO1997029106A1 (en) 1997-08-14
ES2161442T3 (es) 2001-12-01
HUP9900413A3 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
IL124803A0 (en) Coralyne analogs as topoisomerase inhibitors
IL127260A0 (en) Hydroxy-phosphinyl derivatives useful as naaladase inhibitors
IL126951A0 (en) Carboline derivatives
IL130111A0 (en) 6-phenylpyridyl-2-amine derivatives useful as nos inhibitors
HK1024484A1 (en) Thienopyrimidines having pde v-inhibiting action
HK1032049A1 (en) Beta-carboline compounds
HK1022305A1 (en) Naphthyridine derivatives
AP9701020A0 (en) Substituted indazole analogs
GB9600103D0 (en) Improvements to offshore drilling apparatus
IL130572A0 (en) Terbenzimidazoles useful for medical therapy (topoisomerase inhibitors)
IL128667A0 (en) Spirocyclic metalloprotease inhibitors
SG70009A1 (en) Vitamin d3 analogs
PL331562A1 (en) Derivatives of tetraquinoline as antagonists of eaa
AP2001002315A0 (en) Illudin analogs useful as antitumor agents
GB2329134B (en) Improvements to apparatus
PL324034A1 (en) Tribenzimidazoles useful as inhibitors of topoisomerase i
EP0871447A4 (en) WATER-SOLUBLE CAMPTOTHECIN ANALOGS
EP0828743A4 (en) WATER-SOLUBLE CAMPTOTHECIN ANALOG
ZA965318B (en) Camptothecin beta-hydrolactone compounds
ZA9710576B (en) 2-imidazolinylaminoindazole compounds useful as alpha-2-adrenoceptor agonists
EP0910356A4 (en) BIPHENYLAMIDO DERIVATIVES AS MELATONERGIC AGENTS
HU9700273D0 (en) Tetrahydroisoquinoline derivatives
GB9601332D0 (en) New ways to tell the time
ZA982958B (en) Topoisomerase inhibitors
TW306555U (en) Safe structure for safe